The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic
knowledge; and ii) ab initio hazard and risk assessment strategies of chemicals with little background information.
During a poster presentation at the American Society of Nephrology's (ASN) Kidney Week, Regulus will present preclinical results demonstrating the favorable pharmacokinetic and toxicokinetic
properties of RG-012, an anti-miR targeting microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life threatening disease with no approved therapy.
data indicated that the hepatotoxicity induced by triptolide is correlated with its highest concentration in the liver (Xue et al.
2013), or have quantified polymorphic toxicokinetic
variation mainly in drug-metabolizing enzymes (Ginsberg et al.
Ethylene glycol poisoning: toxicokinetic
and analytical factors affecting laboratory diagnosis.
of amphetamines: metabolism and toxicokinetic
data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.
Many, but certainly not all, of the sample analysis performed support pharmacokinetic (PK) and toxicokinetic
The five chapters describe exposure estimation methods, toxicokinetic
and toxicodynamic models, different approaches to mixture effects assessment, test design for mixture concentration-response analysis, and the differences between the whole mixture and component-based approaches to assessing the risk posed by chemical mixtures.
A column-switching high-performance liquid chromatographic assay for a novel cytotoxic thioxanthone derivative (WIN 33377) in mouse plasma with toxicokinetic
results from a mouse LD10 study.
What's different here is that in addition to the usual array of biocompatibility tests it may be necessary to perform a toxicokinetic
study in an in vivo test model in combination with physicochemical tests.
Using an international standard of hair to blood ratio of 250, a steady-state single compartment toxicokinetic
model (2) (see equation 1) and a 5-fold uncertainty factor to account for inter-individual variability, Health Canada developed the pTDI for pregnant women, women of reproductive age and infants, set at 0.
Such models will facilitate more rigorous quantitative analysis of the available toxicokinetic
data for Mn and will be used to identify situations that may lead to increased brain accumulation related to altered Mn metabolism in different human populations, and develop quantitatively accurate predictions of increased Mn levels that may serve as a basis of dosimetry-based risk assessment (79).